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Abstract
Background: Poor sleep quality is common in rheumatoid arthritis (RA) patients and may lead to disease
aggravation and decreased health-related quality of life (HRQoL). The increasing prevalence of poor sleep in RA
patients is associated with adverse demographic, clinical, and psychological characteristics. However, there are
currently no known reported studies related to the effects of sleep quality on HRQoL in RA patients from China.
This cross-sectional study aims to evaluate the contributors of poor sleep and the effects of sleep quality on HRQoL
in Chinese RA patients.
Methods: A self-report survey was administered to 131 RA patients and 104 healthy individuals using the Pittsburgh
Sleep Quality Index (PSQI) for sleep quality. RA patients completed the Hospital Anxiety and Depression Scale for
anxiety and depression, the 28-joint Disease Activity Score for disease activity, the 10 cm Visual Analog Scale for pain,
the Health Assessment Questionnaire-Disability Index for functional capacity and the Short Form 36 health survey
for HRQoL. Blood samples were taken to gain some biochemical indicators (e.g., erythrocyte sedimentation rate,
C-reactive protein, rheumatoid factor, and anti-cyclic citrullinated peptide). Independent samples t-tests, Chi square
analysis, logistic regression modeling and linear regression were used to analyze these data.
Results: Our results found that the prevalence of poor sleep (PSQI ≥ 5) was 78.6% and the mean global score of
PSQI was 7.93 (SD 3.98) in patients, which were significantly higher than the controls (18.7% and 3.88 (SD 1.89),
respectively). There were significant correlations among synthetic disease-modifying antirheumatic drugs, erythrocyte
sedimentation rate, pain, disease activity, functional capacity, anxiety/depression and sleep quality in RA patients.
Meanwhile, logistic regression models identified disease activity and depression as predictors of poor sleep quality.
Poor RA sleepers had impaired HRQoL than good RA sleepers, and sleep quality was independently and significantly
associated with social function and mental components summary.
Conclusions: The majority of Chinese RA patients suffered from poor sleep, which significantly impairs their HRQoL.
The data suggested the need for holistic assessment and management of RA patients and the importance of
objective interventions to improve their sleep quality and finally to improve their HRQoL.
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Background
Rheumatoid arthritis (RA) is a chronic, inflammatory,
autoimmune disorder characterized by joint pain, joint
swelling and destruction of synovial joints. RA influences
about 0.5–1% of adults in industrialised countries and
causes disability, pain, psychological problems and de-
creased quality of life [1–3]. Sleep quality is an important
component of health-related quality of life (HRQoL), and
it has been reported that sleep problems significantly
negatively affect the HRQoL in patients with RA [4].
Therefore, identifying factors contributing to poor sleep
quality and studying the effects of sleep quality on HRQoL
in RA patients is of great importance.
Poor sleep is one of the most prevalent and burdening
symptoms and can have debilitating effect on physical
and/or mental function and health [5]. It has been
reported that sleep problems occur in 54% − 70% of RA
patients, including difficulty falling asleep, poor sleep
quality, non restorative sleep, wakefulness, awakenings
during the night and excessive daytime sleepiness [6, 7].
Importantly, poor sleep quality may contribute to greater
pain, disease activity and mood disorders, creating a
cascade of dysfunction for afflicted patients [8, 9]. It
has been recognized that a number of influences, such
as socioeconomic status, disease activity and psycho-
logical disorders may impact sleep health, which is
common in the RA population [10, 11].
Despite the importance of sleep quality in RA patients,
only a limited number of studies related to RA patients’
sleep quality have been conducted in China. The aim of
this study is (1) to determine contributors of sleep quality
in RA patients recruited from China; (2) to evaluate the
effects of sleep quality on various dimensions of HRQoL
in Chinese RA patients.
Methods
Participants
Patients who fulfilled the American College of Rheuma-
tology (ACR) (2012) criteria for RA were recruited
from the Affiliated Hospital of Nantong University
from December 2014 and to December 2015 [12]. RA
patients were outpatients or inpatients and healthy
subjects were selected from a population attending for
an annual examination. Patients were excluded based
on either of the following: (1) they were less than
18 years old; (2) they did not complete questionnaires;
(3) they had comorbidities (e.g., serious infections, or
cardiac, respiratory, gastrointestinal, endocrine disease)
that could influence disease activity; (4) they did not
complete the measurements of disease activity and
pain. Control subjects were excluded if they exhibited
current or history of other systemic diseases or psychi-
atric disorders. The study was approved by the Ethics
Committee of the Affiliated Hospital of Nantong
University (2014-387), and written informed consents
were obtained from all of the participants, according to
the Declaration of Helsinki.
Demographics and clinical characteristics
Demographic variables contain the following: body mass
index (BMI), gender, age, marital status, education, oc-
cupation, and monthly income, smoking and alcohol
use, which were obtained by a self-designed question-
naire. Clinical variables of disease duration, family
history and medications use were obtained by asking
patients or viewing medical records. Additional clinical
variables of erythrocyte sedimentation rate (ESR), C-
reactive protein (CRP), rheumatoid factor (RF), and
anti-cyclic citrullinated peptide (anti-CCP) were exam-
ined at the time of investigation. ESR and CRP were
assessed by the Westergren method (mm/h) and the
nephelometric method (mg/L), respectively. RF was
measured by immunoturbidimetry using Cobas integra
RFII (Roche Diagnostics GmbH, Mannheim, Germany)
and anti-CCP was measured by enzyme linked immuno-
sorbent assay (ELISA) using DIASTAT™ (Axis-Shield
Diagnostics, Dundee, UK) [13].
Disease activity was estimated with the valid and re-
liable 28-joint Disease Activity Score (DAS28), incor-
porating 28 swollen and tender joint counts, patient’s
assessment of disease activity (0–100 mm VAS, where
0 = not active at all and 100 = extremely active), ESR
(mm/h) and CRP (mg/L) [14].
Pain was measured by the Visual Analogue Scale
(VAS) to characterize clinical pain severity. Patients
were asked to rate their experience of pain during the
last week, each on a VAS of 0–10, with a higher score
indicating more severe pain [15].
Functional capacity was measured by using the Health
Assessment Questionnaire -Disability Index (HAQ-DI).
The HAQ-DI assesses the patient’s perceived difficulty in
completing tasks in eight categories-dressing, arising,
eating, walking, hygiene, reach, grip, and usual activities.
The eight category scores were averaged into an overall
HAQ-DI score and may range from 0 (no disability) to 3
(completely disabled). The Chinese HAQ-DI is a reliable
and valid instrument for studies measuring disability of
patients with RA [16]. “The test-retest reliability coeffi-
cient was 0.84. Between dimensions measured in HAQ-
DI, the highest test-retest reliability was observed for
walking (Spearman correlation coefficient rs = 0.80) and
the lowest was for eating (rs = 0.54). The internal
consistency of the scale using Cronbach's alpha was high
at 0.86” [16].
Assessment of psychological parameters
Psychological status was measured using the Hospital
Anxiety and Depression Scale (HADS), which is divided
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into HADS-A and HADS-D, both of which containing
seven intermingled items [17]. Each item had a 4-point
Likert scale and was scored between 0 and 3. Scores for
each subscale were constructed by summation, ranging
0 − 21. The Chinese version of HADS had acceptable
internal consistency and test-retest reliability, with a
Cronbach alpha of 0.85 and intraclass correlation coef-
ficient of 0.90, respectively [18].
Assessment of self-reported life quality
Participants’ health status was assessed using the Short
Form 36 health survey (SF-36) in the past 4 weeks. It
assessed eight domains (scores range from 0 to 100, with
higher scores indicating better health status): physical
function (PF); role limitations due to physical problems
(RP); body pain (BP); general health perception (GH);
energy/vitality (VT); social function (SF); role limitations
due to emotional problems (RE); mental health (MH).
Z-transformed and normalized domain scores were
grouped into Physical Component Summary (PCS) and
Mental Component Summary (MCS) [19]. The ques-
tionnaire was culturally adapted and translated into
Chinese. “Convergent validity and discriminant validity
were satisfactory for all except the social functioning
scale. Cronbach’s α coefficients ranged from 0.72 to 0.88
except 0.39 for the social functioning scale and 0.66 for
the vitality scale. Two weeks test-retest reliability coeffi-
cients ranged from 0.66 to 0.94” [20].
Assessment of self-reported sleep quality
Sleep quality was examined by the Chinese version of
Pittsburgh Sleep Quality Index (PSQI) during the month
preceding, which includes 19 questions completed by
the subject [21]. Previous studies have found that PSQI
is a well-established, commonly used measure of sleep
quality that has been applied across a range of adult
populations, including those with RA and other medical
conditions [22]. These 19 items were broken down into
the following seven components: subjective sleep quality,
sleep latency, sleep duration, habitual sleep efficiency,
sleep disorders, use of hypnotics, and daytime dysfunction.
The seven components were each scored from 0 (no diffi-
culty) to 3 (severe difficulty), and summed, to give an
overall score ranging from 0 to 21. Participants were di-
chotomized into a poor-sleep group if the PSQI was ≥5.0
and a good-sleep group if the PSQI was < 5.0 [23].
Data collection
Resultant Chinese paper-based questionnaires were
used to administer all instruments under physician
supervision. Administration was performed in a single
sitting, lasting from 15 to 20 min. Pain and DAS28
were evaluated by the same clinician for all patients.
Results were added to a computer database by two
research assistants and double checked against the ori-
ginal data prior to analysis.
Data analysis
Descriptive statistics are provided using mean (±standard
deviation (SD)) or number (percentage) depending on
parametric distribution of measured variables. Potential
demographic, clinic and psychological variables were
screened using univariate tests of the group difference
(poor sleepers versus good sleepers according to the
PSQI), at a lenient level of significance without correction
for multiple testing (alpha = 0.05). The differences in
terms of continuous and categorical variables that are
studied in RA patients who are grouped as poor sleepers
and good sleepers were evaluated with the two-tailed t test
and the chi-square test respectively, as well as the
differences between the RA patients and the controls.
All variables with a significant association with sleep
quality by univariate tests were entered into a multiple
stepwise logistic regression model with the dichoto-
mous sleep quality measured by the PSQI as the
dependent variable. The relations between quality of
life and the other evaluation parameters were examined
with Spearman rank correlation analysis. Linear regres-
sion analysis was used for each of the SF-36 compo-
nents to determine independent association of sleep
quality with quality of life in patients with RA after
controlling for related factors, which have a significant
association with each component of SF-36 by Spearman
rank correlation analysis. Statistical significance was
considered when p <0.05 (two-sided). All analyses were
performed using SPSS version 20.0.
Results
Patient characteristics
As four RA patients and five healthy individuals did not
complete the questionnaires, 131 RA patients (19 males
and 112 females) and 104 healthy individuals (16 males
and 88 females) were enrolled in the current study.
Table 1 presents the baseline participant characteristics
included in our study. Of the 131 RA patients included
in this analysis, 85.5% were female and the mean (SD)
age was 54.7(11.5) years. Almost 98.5% RA patients
were treated with synthetic Disease-Modifying Antirheu-
matic Drugs (DMARD) and the mean (SD) ESR was
28.47 (27.64) mm/h. There was no significant difference
in the age, gender, BMI, marital status, education, occupa-
tion, income/month, alcohol and smoke between the RA
individuals and the controls (p > 0.05).
Self-reported sleep quality
In the present study, we found that 103 of the 131 patients
with RA had a high risk for poor sleep quality. The results
demonstrated that the prevalence of poor sleep (PSQI ≥ 5)
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in RA patients (78.6%) was higher than in the controls
(18.7%) and the total PSQI score of patients with RA was
significantly higher than that of the controls (7.93 ± 3.98
versus 3.88 ± 1.89; p < 0.01). Table 2 summarized the
global score and the component scale scores of the PSQI
for our RA sample in comparison with controls. The
data showed that five of the seven components of PSQI
in RA patients were significantly different from the con-
trols: subjective sleep quality, sleep latency, habitual
sleep efficiency, sleep disorders and use of hypnotics.
Differences between good and poor sleepers in RA patients
As shown in Table 3, a number of demographic, clinical
and psychological variables were tested for possible
differences between good sleepers and poor sleepers in
patients. Poor sleepers had higher disease activity scores,
higher level of ESR, severer total/nocturnal pain, higher
degree of depression and anxiety, with a trend toward
lower functional capacity as well, compared with good
sleepers (p < 0.05). In addition, the percentage of synthetic
DMARDs use in good sleep patients was significant higher
than that of poor sleep patients (p < 0.05).
Determinants of self-reported sleep quality in RA patients
We used stepwise multiple logistic regression analysis
to investigate predictors of sleep quality, as indicated in
Table 4. We found that HADS-D(β = 0.340, p < 0.01)
and DAS28 (β = 0.520, p < 0.01) were the predictors of
sleep quality.
Effects of self-reported sleep quality on HRQoL
Comparison of poor sleepers and good sleepers in terms
of HRQoL was summarized in Table 5. Patients with
poor sleep quality had significantly lower HRQoL in all
domains of the SF-36 scale. The relations between
HRQoL and the other evaluation parameters were exam-
ined with Spearman rank correlation analysis (Additional
file 1: Table S1). Considering observed associations of
demographic, disease-related and psychological factors







Gender, female, N (%) 112 (85.5) 88 (84.6) 0.79
BMI (kg/m2), Mean ± SD 22.5 ± 3.12 22.84 ± 2.81 0.432
Age (years), Mean ± SD 54.5 ± 11.5 54.77 ± 11.20 0.851
Monthly income (yuan), N (%) 0.973
<1000 67 (51.1) 55 (52.9)
1000-3000 47 (35.9) 35 (33.7)
3000-5000 13 (9.9) 10 (9.6)
>5000 4 (3.1) 4 (3.8)
Marital status, N (%) 0.411
Single 7 (5.3) 11 (10.6)
Married 118 (90.1) 90 (86.5)
Divorced 1 (0.8) 1 (1.0)
Widowed 5 (3.8) 2 (1.9)
Education, N (%) 0.571
≤9 years 93 (71.0) 70 (76.9)
>9 years 38 (29.0) 34 (23.1)
Occupation, N (%) 0.757
Employed 102 (77.9) 80 (80.8)
Unemployed 29 (22.1) 24 (19.2)
Alcohol use, yes, N (%) 24 (18.3) 19 (18.3) 1.000
Smoking use, yes, N (%) 10 (7.6) 10 (9.6) 0.642
Disease duration (years), Mean ± SD 8.7 ± 9.1
Family history, yes, N (%) 10 (7.6)
Medications use, N (%)
NSAIDs 692 (52.7)
Synthetic DMARDs 129 (98.5)
Biologic DMARDs 11 (8.4)
Glucocorticoid 62 (47.3)
ESR (mm/h), Mean ± SD 28.47 ± 27. 64
CRP (mg/L), Mean ± SD 16.61 ± 24.51
RF positive, N (%) 102 (77.9)
anti-CCP positive, N (%) 91 (69.5)
DAS28, Mean ± SD 3.96 ± 1.44
HAQ-DI, Mean ± SD 0.50 ± 0.61
Total pain (VAS), Mean ± SD 4.32 ± 2.76
Nocturnal pain (VAS), Mean ± SD 3.95 ± 3.22
HADS-A, Mean ± SD 9.12 ± 2.79
HADS-D, Mean ± SD 8.74 ± 2.46
Data are means ± SD for continuous variables, or percentages for
categorical variables
p values were obtained with the chi-square test for categorical variables and
the two-tailed t test for continuous variables
BMI Body Mass Index, NSAID Nonsteroidal anti-Inflammatory Drugs, DMARD
Disease-Modifying Antirheumatic Drugs, ESR Erythrocyte Sedimentation Rate,
CRP C-reactive Protein, RF Rheumatoid Factor, anti-CCP anti-cyclic citrullinated
peptide, DAS28 Disease Activity Score in 28 Joints, HAQ-DI Health Assessment
Questionnaire-Disability Index, VAS Visual Analog Scale, HADS Hospital Anxiety
and Depression Scale, SF-36 the Medical Outcomes Study Short Form 36,
PCS Physical Components Summary, MCS Mental Components Summary,
PSQI Pittsburgh Sleep Quality Index
Table 2 Comparison of the components of PSQI in cases and
controls
PSQI components score Cases (n = 131) Controls (n = 104) p
Subjective sleep quality 1.23 ± 0.74 0.63 ± 0.73 <0.001
Sleep latency 1.70 ± 1.04 0.70 ± 0.74 <0.001
Sleep duration 0.80 ± 1.05 0.70 ± 1.00 0.451
Habitual sleep efficiency 1.16 ± 1.19 0.15 ± 0.41 <0.001
Sleep disorders 1.65 ± 0.69 0.90 ± 0.72 <0.001
Use of sleep medications 0.52 ± 1.04 0.06 ± 0.27 <0.001
Daytime dysfunction 0.88 ± 0.74 0.73 ± 0.80 0.148
Total 7.93 ± 3.98 3.88 ± 1.89 <0.001
Data are means (standard deviation) for continuous variables
p values were obtained with the two-tailed t test
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with sleep quality, we conducted linear regression analysis
for each of the SF-36 components to determine indepen-
dent association of sleep quality with quality of life after
controlling for related factors, which have a significant
association with each component of SF-36 by Spearman
rank correlation analysis. The results showed that sleep
quality was independently and significantly associated
with SF (β = -0.204, p = 0.012) and MCS (β = -0.158, p =
0.037). Sleep quality was not significantly associated with
the remained components of SF-36 (Table 6).
Discussion
Sleep problems are common in patients with chronic
diseases and the prevalence of poor sleep is high in RA
patients compared to controls [24–26]. In the current
study, 78.6% of RA patients suffered from poor sleep,
and disease activity and depression were independent
predictors of poor sleep quality in RA patients. What is
more, poor RA sleepers had impaired HRQoL than good
RA sleepers and sleep quality was independently and
significantly associated with HRQoL. To our knowledge,
this is the first examination of the effects of sleep quality
on HRQoL in Chinese RA patients.
Table 3 Comparison between poor and good sleepers in
RA patients
Variables PSQI < 5 (n = 28) PSQI ≥ 5 (n = 103) p
Female 22 (78.6) 90 (87.4) 0.240
BMI (kg/m2) 22.88 ± 3.40 22.39 ± 3.01 0.347
Age (years) 54.79 ± 12.08 54.38 ± 11.45 0.872
Disease duration (years) 8.21 ± 8.99 8.83 ± 9.15 0.749
Monthly income (yuan) 0.141
<1000 12 (426.9) 55 (53.4)
1000-3000 9 (32.1) 38 (36.9)
3000-5000 6 (21.4) 7 (6.8)
>5000 1 (3.6) 3 (2.9)
Marital status 0.273
Single 1 (3.6) 5 (4.9)
Married 25 (89.3) 94 (91.3)
Divorced 1 (3.6) 0 (0)
Widowed 1 (3.6) 4 (3.9)
Education 0.240
≤9 years 17 (60.7) 76 (73.8)
>9 years 11 (39.3) 27 (26.2)
Occupation 0.798
Employed 21 (75.0) 81 (78.6)
Unemployed 7 (25.0) 22 (21.4)
Smoking use, yes 4 (14.3) 6 (5.8) 0.220
Alcohol use, yes 4 (14.3) 20 (19.4) 0.783
Family history 2 (7.1) 8 (7.8) 1.000
Medications use
NSAIDs 17 (60.7) 52 (50.5) 0.396
Synthetic DMARDs 26 (92.9) 103 (100.0) 0.044
Biologic DMARDs 2 (7.1) 9 (8.7) 1.000
Glucocorticoid 11 (39.3) 512 (49.5) 0.396
ESR (mm/h) 19.14 ± 15.96 31.00 ± 29.39 0.006
CRP (mg/dl) 12.36 ± 25.00 17.7668 ± 24.37 0.336
RF positive 19 (67.9) 84 (80.6) 0.198
anti-CCP positive 19 (67.9) 72 (69.9) 0.821
DAS28 3.15 ± 1.39 4.17 ± 1.38 0.001
HAQ-DI 0.20 ± 0.38 0.52 ± 0.65 0.002
Total pain (VAS) 2.96 ± 1.86 4.69 ± 2.85 0.001
Nocturnal pain (VAS) 2.66 ± 2.54 4.30 ± 3.30 0.007
HADS-A 8.00 ± 2.46 9.42 ± 2.81 0.016
HADS-D 7.25 ± 1.76 9.03 ± 2.49 0.001
Data are means ± SD for continuous variables, or percentages for
categorical variables
p values were obtained with the chi-square test for categorical variables and
the two-tailed t test for continuous variables
BMI Body Mass Index, NSAID Nonsteroidal anti-Inflammatory Drugs, DMARD
Disease-Modifying Antirheumatic Drugs, ESR Erythrocyte Sedimentation Rate,
CRP C-reactive Protein, anti-CCP anti-cyclic citrullinated peptide, RF Rheumatoid
Factor, DAS28 Disease Activity Score in 28 Joints, HAQ-DI Health Assessment
Questionnaire-Disability Index, VAS Visual Analog Scale, HADS Hospital Anxiety
and Depression Scale, SF-36 the Medical Outcomes Study Short Form 36,
PCS Physical Components Summary, MCS Mental Components Summary,
PSQI Pittsburgh Sleep Quality Index
Table 4 Stepwise multiple logistic regression analysis of
demographic, medical and psychological variables in relation
to PSQI in RA patients
Predictors β SE p Exp(B) 95%CI
Lower Upper
HADS-D 0.340 0.122 0.007 1.406 1.106 1.786
DAS-28 0.520 0.193 0.004 1.681 1.152 2.453
p values were obtained with stepwise multiple logistic regression analysis
DAS28 Disease Activity Score in 28 Joints, HADS Hospital Anxiety and
Depression Scale, PSQI Pittsburgh Sleep Quality Index
Table 5 Comparison between poor and good sleepers in
RA patients
Variables PSQI < 5 (n = 28) PSQI≥ 5(n = 103) p
PF 69.82 ± 28.07 54.27 ± 28.43 0.015
RP 41.07 ± 48.70 17.23 ± 32.09 0.020
BP 60.79 ± 24.72 44.91 ± 25.54 0.004
GH 54.86 ± 21.70 38.29 ± 19.72 <0.001
VT 63.39 ± 17.69 48.59 ± 18.03 <0.001
SF 75.89 ± 26.12 58.62 ± 26.55 0.003
RE 54.76 ± 46.45 31.39 ± 41.96 0.012
MH 71.29 ± 18.48 58.56 ± 17.56 0.002
SF-36 PCS 56.63 ± 24.63 38.68 ± 19.95 0.001
SF-36 MCS 66.33 ± 22.72 49.30 ± 20.27 0.001
p values were obtained with the two-tailed t test for continuous variables
PF physical function, RP role limitations due to physical problems, BP body
pain, GH general health perception, VT energy/vitality. SF social function, RE
role limitations due to emotional problems, MH mental health, PCS Physical
Components Summary, MCS Mental Components Summary, PSQI Pittsburgh
Sleep Quality Index
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It has been reported that several factors of demographic,
clinical and psychogenic variables have an influence on
sleep quality [27–29]. In our study, patients with a PSQI
score ≥5 were found to have significantly more frequently
use synthetic DMARDs. However, Nicassio PM et al.
examining sleep disturbance in RA patients have found no
association between synthetic DMARDs and sleep quality
[30]. While, one study has shown that YORA (age at
disease onset ≤ 65 years) patients reported more sleep
disorders and received significantly more synthetic
DMARDs than LORA (age at disease onset > 65 years) RA
patients [31]. In our present study, the majority of RA
patients were under 65 years and 98.5% patients had syn-
thetic DMARDs, which may account for the differences in
our findings compared to other reported findings [30].
An increasing number of studies have indicated that
psychological disorders are risk factors for sleep quality
[4, 32, 33]. It has been reported that 20% − 30% of RA
patients have significant mood problems [9, 34]. Psycho-
logical disorders especially depression aggravate the nu-
merous health-related comorbidities that are related to
RA such as disability and limitations in quality of life
[35, 36]. In the present study, we also found that poor-
sleep patients had significantly higher levels of HADS-A
and HADS-D scores compared with good-sleep patients.
Interestingly, logistic regression analysis indicated that
depression was a major contributor to sleep quality,
which is consistent with previous studies [28, 30]. The
data suggested the need for systemic psychiatric screening
and management and the importance of targeted inter-
ventions to help RA patients get rid of sleep problems
[30]. At present, some non-pharmacological treatments,
such as intermittent aerobic exercise, can relieve depres-
sion and anxiety, as well as improving sleep quality in RA
patients [37]. Meanwhile, it is reported that sleep manage-
ment including sleep education and cognitive-behavioral
interventions can improve physical/mental wellness and
sleep quality [38].
Previous study has found that disease activity has a
vital effect on sleep quality in RA patients [33, 34].
Westhovens et al. examining sleep problems in patients
with RA have found a positive and independent associ-
ation between disease activity and sleep quality [29]. Our
study has shown poor-sleep patients had significantly
higher levels of disease activity compared with good-
sleep patients. Importantly, logistic regression analysis
indicated that disease activity is a major contributor to
sleep quality, which is consistent with previous studies
from Turkey and Korea [4, 27]. Additionally, the ESR
was found to be associated with sleep quality in our
study, which was in line with prior research reports [4].
It is possible that ESR more closely correlated with poly-
somnography parameters recorded during sleep hypoxic
episodes and moderate and severe obstructive sleep
apnea were independently associated with an elevated
ESR [39]. Also, there was a positive correlation between
sleep quality and pain in RA patients, which was also
found in our study [32]. Unexpectedly, pain did not con-
tribute to poor sleep quality in the logistic regression
analysis of our study, which was different from a previous
study [30]. The possible explanation may be that the active
inflammatory disease and the resulting pain are treated
and the arthritic process is stopped, which resulted in less
influence than other variables on sleep quality [40].
Similar to the results of Wolfe et al., the data in the
present study support that functional capacity is associ-
ated with sleep quality [32]. The inability to perform the
daily activities may cause depression and lead to poor
sleep quality in RA patients [41]. After administration of
the IL-6 receptor antagonist tocilizumab in patients with
RA, changes in PSQI score over time were correlated
significantly with HAQ-DI changes and marginally
with changes in fatigue [42]. Therefore, IL-6 may play
an important role in the mechanism of sleep quality.
HRQoL is considered as one of the main outcome
measures for RA patients and sleep quality represents a
central component of HRQoL in RA patients [4]. Several
studies have shown that individuals with RA have poorer
quality of life compared to the general population, in both
the emotional and physical domains [43, 44]. We found
diminished HRQoL in poor sleepers in all dimensions of
Table 6 Linear regression analysis of sleep quality on each of
the SF-36 components











p values were obtained with multiple linear regression analysis
acontrolled for income, disease duration, ESR, CRP, DAS28, total pain, nocturnal
pain, HAQ-DI, and HADS. bcontrolled for income, synthetic DMARDs, CRP,
DAS28, total pain, nocturnal pain, HAQ-DI, and HADS. ccontrolled for income,
synthetic DMARDs, CRP, RF, DAS28, total pain, nocturnal pain, HAQ-DI, and
HADS. dcontrolled for age, alcohol, disease duration, synthetic DMARDs,
DAS28, total pain, nocturnal pain, HAQ-DI, and HADS. econtrolled for income,
disease duration, ESR, CRP, DAS28, total pain, nocturnal pain, HAQ-DI, and
HADS. fcontrolled for age, income, synthetic DMARDs, ESR, CRP, RF positive,
anti-CCP positive, DAS28, total pain, nocturnal pain, HAQ-DI, and HADS.
gcontrolled for age, income, synthetic DMARDs, ESR, CRP, RF positive,
DAS28, total pain, nocturnal pain, HAQ-DI, and HADS. hcontrolled for occupation,
income, ESR, CRP, DAS28, total pain, nocturnal pain, HAQ-DI, and HADS.
icontrolled for income, disease duration, synthetic DMARDs, ESR, CRP,
DAS28, total pain, nocturnal pain, HAQ-DI, and HADS
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SF-36 compared with good sleepers. Association between
sleep quality remained significant for SF and MCS after
controlling for demographic, disease-related and psycho-
logical factors. It is of interest that RA patients had poorer
HRQoL, including general health, physical health, mental
health and sleep [45]. Associations of sleep problems with
pain and fatigue in RA patients are also reported by some
previous studies [46]. It must be noted that fatigue and
pain in RA patients are multidimensional with physical
and mental health. The HRQoL instrument we used in
our study was not comprehensive in this regard, which
may explain our results.
Though we reported the relationship between the
demographic, clinical, psychological characteristics and
sleep quality and the effects of sleep quality on HRQoL
in Chinese patients with RA, we also had several limita-
tions: (1) We just measure sleep quality and psycho-
logical factors with self-report questionnaires. (2) Since
the sample size was rather small and was from a single
clinic of rheumatology, findings of this study cannot be
generalized to all RA patients in our society. (3) The
cross-sectional design of our study does not allow examin-
ing causal relationships between variables. Further studies
with expanded sample sizes, objective sleep measures and
prospective studies on RA patients’ quality of sleep should
be conducted to support the development of effective
interventions to improve their sleep quality.
Conclusions
In summary, this is the first known evaluation of the
contributors of poor sleep quality and the effects of sleep
quality on RA patients’ HRQoL in China. The present
study has found that the quality of sleep was very poor
in RA patients and that poor sleep quality may signifi-
cantly impair their HRQoL. The results of this research
provided evidence of the importance of disease activity
and depression in explaining sleep quality in patients
with RA. The results emphasize the need for systemic
psychiatric screening, holistic assessment and targeted
intervention/management of RA patients to improve
their sleep quality and finally improve their HRQoL.
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